Research Solutions, Inc. (RSSS)

Executive Summary / Key Takeaways

• Thesis: Research Solutions is executing a critical transformation from a declining transaction business into a high-margin, AI-powered vertical SaaS platform, with Platform ARR reaching $21.8 million (14% YoY growth) and gross margins expanding to 88%. The pace of this transition will determine whether the stock re-rates or stagnates.

• Strategic Differentiation: The company's "headless" API-first strategy is creating stickier customer relationships, with deals 2-5x larger than traditional seat-based sales as customers embed citation graphs, rights management, and paywall access directly into their AI infrastructure.

• Financial Inflection: FY2025 marked the first time adjusted EBITDA margin exceeded 10% (reaching 11.8% trailing), driven by the revenue mix shift toward Platforms (44% of total revenue in Q2 FY26) and operational leverage, generating over $7 million in operating cash flow.

• Key Risk: The legacy Transactions segment declined 10% in Q2 FY26 as AI-driven "zero-click search" reduces article downloads, creating a race where Platform growth must outrun Transaction decay while facing intensifying B2C competition.

• Critical Variables: Success hinges on whether the company can stabilize Transaction declines through product innovation and return Platform growth to 20%+ rates, while managing B2C competitive pressures and scaling its API infrastructure to capture the emerging AI research market before larger competitors consolidate their own offerings.

Setting the Scene: The STM Content Market Meets AI Disruption

Research Solutions, incorporated in Nevada in November 2006, operates at the intersection of scientific publishing and artificial intelligence. The company provides two distinct service lines: a high-margin Platforms segment offering SaaS tools for scientific research workflow, and a transaction-based document delivery business that provides on-demand access to over 200 million scientific, technical, and medical (STM) articles. This dual structure represents the company's evolution from a content reseller to an AI infrastructure provider.

The STM research ecosystem is experiencing a structural shift driven by generative AI. Traditional metrics like article downloads and full-text reads are declining as researchers increasingly use AI tools for "zero-click search"—getting answers directly from language models without accessing source documents. This trend directly threatens the Transactions segment while simultaneously creating demand for Platform solutions that provide verified, copyright-compliant citations and paywall access. The market is bifurcating: commodity article access is being disintermediated by AI, while infrastructure that makes AI trustworthy and compliant is becoming more valuable.

Research Solutions occupies a niche position against dominant incumbents. Clarivate (CLVT) controls Web of Science with 250 million citations, RELX (RELX) commands 25% of STM publishing through ScienceDirect and Scopus, and Wolters Kluwer (WKL) serves clinical markets with UpToDate and Ovid. These competitors generate billions in revenue with 25-35% operating margins. RSSS has carved out a distinct role as a neutral, publisher-agnostic infrastructure layer—a positioning that becomes strategically valuable as enterprises seek to integrate multiple content sources into AI workflows rather than remain locked into single-publisher ecosystems.

Technology, Products, and Strategic Differentiation: Building the "Answers and Access" Platform

The company's transformation centers on its 2023 acquisitions of ResoluteAI and Scite, which provided the curated databases and "smart citations" technology that power its AI-generated output. This was a strategic repositioning from selling seats to selling infrastructure. This shift matters because it fundamentally changes the revenue model: API deals are typically 2-5x larger than traditional seat-based sales and become embedded as mission-critical infrastructure, reducing churn and increasing lifetime value.

The "Answers and Access" strategy addresses AI's core weakness in scientific research. While general LLMs hallucinate and lack access to paywalled content, Research Solutions' Platform combines Scite's smart citations—which expose actual in-text citation statements and indicate whether claims are supported or contradicted—with Article Galaxy's rights management and entitlement systems. This creates a retrieval-augmented generation framework that delivers highly accurate results with low hallucination incidence. The company is positioned as the compliance and verification layer that makes AI usable in regulated research environments.

The "headless strategy" represents the commercial manifestation of this advantage. By decoupling services from a fixed UI and offering APIs that embed citation graphs, evidence summaries, and rights-cleared content directly into customer workflows, Research Solutions becomes the infrastructure powering other companies' AI tools. One large pharma customer already makes over 1 million API calls annually, and publishers are discussing using the company's infrastructure to offer AI access to their content without building their own copyright systems. This transforms the business model from per-user subscriptions to usage-based infrastructure, with pricing models based on API calls rather than seats.

Financial Performance & Segment Dynamics: The Mix Shift in Action

The Q2 FY26 results provide evidence of the thesis playing out. Platform revenue grew 14% to $5.22 million with 88.1% gross margins, while Transaction revenue declined 10% to $6.57 million with 24% gross margins. The consolidated gross margin improved 350 basis points to 52.4%, driven by this mix shift. The significance lies in the fact that every dollar of Platform revenue generates $0.88 of gross profit versus just $0.24 from Transactions, meaning Platform growth creates 3.7x more gross profit per dollar of revenue.

The segment dynamics reveal a business at an inflection point. Platform ARR reached $21.8 million, representing 44% of total revenue, up from 39% in the prior year quarter. The company added 47 net new platform deployments in Q2 FY26, the highest organic second quarter in company history. Management explicitly chose to prioritize cohort quality over short-term B2C growth, a decision that temporarily slows top-line growth but builds a more durable recurring revenue base. This trade-off signals management discipline in optimizing for lifetime value and retention.

Cash flow generation validates the strategy's financial sustainability. The company generated $2.49 million in operating cash flow in the first six months of FY26, ending with $12.3 million in cash and no borrowings on its revolving credit facility. FY2025 produced over $7 million in operating cash flow, nearly double the prior year, while funding the Scite acquisition earn-out payments entirely from operations. This demonstrates that the Platform business is generating sufficient cash to fund strategic investments without diluting shareholders or taking on debt.

Outlook, Management Guidance, and Execution Risk

Management's guidance for FY26 reveals both confidence and realism. They expect to exceed FY25 EBITDA levels in each remaining quarter while continuing to invest in sales and marketing, targeting a weighted Rule of 40 score of 40+. The weighted formula (ARR growth × 1.33 + EBITDA margin × 0.67) prioritizes growth over profitability, with the current trailing score at 33.1. This shows management is intentionally sacrificing near-term margin expansion to capture the AI infrastructure opportunity.

The Transaction revenue outlook remains challenging but potentially stabilizing. Management expects the decline to continue in H2 FY26, driven by one known churned account and reduced volume from a few large customers, but they are optimistic about a flattening of the decline by year-end. Excluding the churned account, Transaction declines were only 2% year-over-year, suggesting the underlying business is stable. The key execution risk is whether product improvements can offset the secular headwind of AI reducing individual article downloads.

The B2C segment presents a near-term headwind but long-term opportunity. Increased competitive digital marketing spend has reduced trial-to-subscriber conversion rates. However, the B2C-to-B2B pipeline has grown from $50,000 to over $1 million as individual users advocate for enterprise subscriptions. This demonstrates a viral growth mechanism where product-led adoption in academia and small labs creates inbound enterprise leads.

Risks and Asymmetries: What Could Break the Thesis

The most material risk is AI disruption accelerating faster than the company's Platform pivot. Internal surveys confirm AI is directly causing people to acquire fewer articles. If this zero-click search trend intensifies beyond the ability to innovate in the document delivery space, Transaction revenue could decline faster than Platform ARR can compensate, creating a growth trap where the shrinking legacy business masks Platform success.

Competitive pressure in B2C could erode a key growth engine and lead generation channel. With new entrants spending aggressively on digital marketing, Research Solutions faces a choice: match spend and accept lower returns, or rely on product differentiation. Management has chosen the latter, but this could slow B2C ARR growth enough to impact the overall SaaS growth rate target of 20%+.

Scale disadvantage versus RELX and Clarivate creates long-term strategic vulnerability. While Research Solutions' publisher-agnostic positioning is currently attractive, larger competitors could replicate the API infrastructure model. If these incumbents successfully launch their own Model Context Protocols or AI gateways, Research Solutions could be relegated to serving the "long tail" of smaller publishers, limiting its addressable market.

Valuation Context

Trading at $2.35 per share with a market cap of $77.33 million, Research Solutions trades at 1.57x trailing sales and 10.17x free cash flow. The enterprise value of $65.07 million represents 1.32x revenue and 13.78x EBITDA. These are reasonable multiples for a company transitioning to SaaS with 14% ARR growth and 11.8% EBITDA margins. For context, Clarivate trades at 0.63x sales but with negative margins, while RELX commands 2.87x sales with 21.5% profit margins.

The balance sheet provides strategic optionality. With $12.3 million in cash, no debt, and the ability to fund remaining Scite earn-out payments ($1.2 million quarterly through May 2027) entirely from operating cash flow, the company has the firepower to invest in product development without dilution. The company also has an active M&A pipeline and believes it can finance deals primarily through senior debt and cash, suggesting opportunities to accelerate the Platform strategy through acquisitions.

Conclusion

Research Solutions is executing a business model transformation, shifting from a commoditized transaction business to a high-margin, API-first AI infrastructure platform. The financial evidence includes Platform gross margins at 88%, adjusted EBITDA margins exceeding 10%, and strong cash flow funding strategic investments. The "headless strategy" of embedding citation graphs and rights management into customer AI workflows creates genuine switching costs and larger deal sizes.

The investment case remains balanced. Transaction revenue declines of 10% and B2C competitive pressures are threats that could overwhelm Platform growth if not stabilized. Management's guidance assumes successful execution on multiple fronts: returning Platform growth to 20%+, flattening Transaction declines, and maintaining EBITDA margins. The stock's valuation offers upside if the transformation succeeds, but minimal margin of safety if AI disruption accelerates or larger competitors replicate the API strategy. The critical variables are Q3/Q4 Transaction performance and B2C conversion rates.